Phase-Ib/II-Studie zu Kombinationstherapien mit Pembrolizumab (MK-3475) bei Patienten mit metastasiertem kastrationsresistenten Prostatakarzinom (mCRPC)Phase Ib/II trial of pembrolizumab (MK-3475) combination therapies in metastatic castration-resistant prostate cancer (mCRPC)

被引：0

作者：

H. Rexer

M. Retz

P. Hammerer

机构：

[1] AUO Geschäftsstelle,Klinikum r. d. I., Urologische Klinik und Poliklinik, Klinische Prüfung (LKP)

[2] TU München,Organgruppe Prostatakarzinom, Arbeitsgemeinschaft Urologische Onkologie

[3] Deutsche Krebsgesellschaft e. V.,undefined

来源：

Forum | 2023年 / 38卷 / 1期

关键词：

D O I：

10.1007/s12312-022-01164-7

中图分类号：

学科分类号：

摘要：

引用

页码：82 / 83

页数：1

共 50 条

[1] Phase-II-Studie zu Pembrolizumab (MK-3475) bei Patienten mit metastasiertem kastrationsresistenten Prostatakarzinom (KEYNOTE-199) – Studie AP 93/16 der AUOPhase II study of pembrolizumab (MK-3475) in patients with metastatic castration-resistant prostate cancer (KEYNOTE-199)—study AP 93/16 of the AUO
H. Rexer
M. Graefen
A. Merseburger
[J]. Der Urologe, 2017, 56 (11): : 1471 - 1472
[2] Phase-II-Studie bei Patienten mit metastasiertem kastrationsresistenten Prostatakarzinom (mCRPC)Phase II study with metastatic castration-resistant prostate cancer (mCRPC) patients
H. Rexer
M. Graefen
[J]. Der Urologe, 2017, 56 (11): : 1468 - 1470
[3] Phase Ib/II-Studie beim Patienten mit metastasiertem kastrationsresistentem Prostatakarzinom (mCRPC)
[J]. Forum, 2018, 33 (1) : 44 - 45
[4] Phase Ib/II-Study in Patients with metastatic castration-resistant Prostate Cancer (mCRPC) Phase Ib/II-Study of Pembrolizumab (MK-3475) Combination Therapies in Patients with mCRPC (KEYNOTE-365) - Study AP 94/16 of the AUO
Rexer, H.
Wuelfing, C.
Retz, M.
[J]. UROLOGE, 2018, 57 (01): : 120 - 121
[5] Phase II Cohort Study in Patients with metastatic castration-resistant Prostate Cancer (mCRPC) with new Cohorts Phase Ib/II Study of Combination Therapies with Pembrolizumab (MK-3475) in Patients with mCRPC (KEYNOTE-365) - Study AP 94/16 of the AUO
Rexer, H.
Retz, M.
Hammerer, P.
[J]. UROLOGE, 2022, 61 (01): : 107 - 108
[6] Phase Ib/II study of combination therapies with pembrolizumab (MK-3475) in patients with mCRPC (KEYNOTE-365) - study AP 94/16 of the AUO
Rexer, H.
Retz, M.
Hammerer, P.
[J]. UROLOGIE, 2023, 62 (12): : 1370 - 1371
[7] Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma (cSCC)
Kudchadkar, Ragini Reiney
Yushak, Melinda Lynne
Lawson, David H.
Delman, Keith A.
Lowe, Michael C.
Goings, Monica
McBrien, Stephanie
Mckellar, Marjorie
Sieja, Kristin
Maynard, Necia
Ford, Mandy
Pollack, Brian P.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[8] Phase II Study of Pembrolizumab (MK-3475) in Patients with metastatic castration-resistant Prostate Cancer (KEYNOTE-199)-Study AP 93/16 of the AUO
Rexer, H.
Graefen, M.
Merseburger, A.
[J]. UROLOGE, 2017, 56 (11): : 1471 - 1472
[9] Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma: An updated analysis.
Yushak, Melinda Lynne
Lawson, David H.
Goings, Monica
Mckellar, Marjorie
Maynard, Necia
Woodruff, Kristin Sieja
Gorgoglione, Caroline
McBrien, Stephanie
Delman, Keith A.
Lowe, Michael C.
Kudchadkar, Ragini Reiney
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[10] Phase II trial of dose dense (weekly) paclitaxel with pembrolizumab (MK-3475) in platinum-resistant recurrent ovarian cancer.
Wenham, Robert Michael
Apte, Sachin M.
Shahzad, Mian M.
Lee, Jae K.
Dorman, Denise
Chon, Hye Sook
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →